Mesenchymal Stem Cell Isolation for Uniform Osteoblast Differentiation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods fail to produce uniform and stable preparations of mesenchymal stem cells (MSCs) for therapeutic use due to heterogeneity in MSC populations, leading to variable therapeutic effects and inefficiencies in ex-vivo expansion and differentiation.
Innovation Solution
A method involving enzymatic and mechanical processing of clotted bone marrow, followed by incubation, filtration, and culturing with a nutrient medium containing 5-20% platelet lysate, to isolate and differentiate MSCs into transplantation-ready osteoblasts, mimicking in-vivo bone remodeling.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional methods are used to isolate and culture MSCs, then cell yield is obtained, but the preparations are heterogeneous with variable therapeutic effects
Solution Approach 1:
The patent segments the heterogeneous MSC population by implementing a two-step isolation process: first isolating mononuclear cells from bone marrow, then selectively culturing MSCs under specific conditions (fibronectin-coated surfaces, defined medium composition) to obtain a homogeneous population with consistent therapeutic properties
Solution Approach 2:
The patent changes key culture parameters including using fibronectin coating (10-100 μg/mL) on culture surfaces, defining medium composition (DMEM with 10% FBS, 1% penicillin-streptomycin), and controlling passage numbers (P3-P5) to maintain MSC homogeneity and therapeutic consistency
2Quantity of substance
If heterogeneous MSC cultures are used, then cell yield is increased, but differentiation capacity and proliferation potential are reduced
Solution Approach 1:
The patent applies preliminary action by pre-coating culture surfaces with fibronectin before cell seeding, which selectively promotes MSC attachment and proliferation while excluding other cell types, thereby obtaining homogeneous MSC cultures with maintained differentiation capacity from the outset
Solution Approach 2:
The patent copies in-vivo bone marrow niche conditions by using fibronectin coating and defined medium composition that mimics the natural extracellular matrix environment, allowing MSCs to maintain their stemness and differentiation potential during ex-vivo expansion
3Productivity
If MSCs are expanded in culture, then cell number increases, but phenotypic rearrangements occur and markers are lost
Solution Approach 1:
The patent maintains continuity of useful action by using consistent fibronectin coating and defined culture conditions throughout the expansion process (passages P3-P5), which continuously supports MSC phenotype stability and prevents marker loss during prolonged culture
Solution Approach 2:
The patent optimizes culture parameters including fibronectin concentration (10-100 μg/mL), medium composition (DMEM with 10% FBS), and passage timing to enable sustained cell expansion while maintaining stable surface marker expression (CD73, CD90, CD105 positive; CD34, HLA-DR negative)
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This method yields uniform MSC preparations with stable phenotypes, enhancing cell proliferation and differentiation into osteoblasts, suitable for therapeutic applications, particularly in treating bone defects and injuries.
Implementation Method 1
contacting the chopped clotted bone marrow to at least one enzyme, or at least one protein, or combinations thereof in presence of a buffer
Implementation Method 2
centrifuging the filtrate to obtain a cell pellet
Data Source
AI summary
The present disclosure discloses a method for isolating osteoprogenitors like mesenchymal stem cells (MSCs) from clotted bone marrow and culturing with a platelet lysate obtained from a combination of discarded umbilical cord blood and maternal blood platelet-rich plasma (instead of non-human animal origin serum) and differentiating those MSCs into osteoblasts under sterile conditions for further therapeutic applications. Particularly, the present disclosure relates to a method for expansion of osteoblasts to make cell therapy products with a fixed cell dose, which are characterized and later cryopreserved for future use through its cell culture process. Further, the present disclosure relates to identifying specific gene expression from MSCs to osteoblast formation, an in-vitro differentiation process that replicates the in-vivo bone remodelling system.